BioNTech will announce Q2 2026 financial results on August 4, 2026, with a conference call for stakeholders.
Quiver AI Summary
BioNTech SE announced it will release its financial results for the second quarter of 2026 on August 4, 2026, and will host a conference call and webcast at 8:00 a.m. ET that day to discuss these results and provide a corporate update. The event is open to investors, analysts, and the public, with registration required for dial-in access. BioNTech is focused on developing innovative therapies for cancer and other serious diseases, with a strong late-stage oncology pipeline that includes various treatment approaches. The company collaborates with several pharmaceutical partners to enhance its research and development efforts. Further details can be found on BioNTech's website.
Potential Positives
- BioNTech is poised to share its financial results for the second quarter of 2026, indicating transparency and accountability to its investors and stakeholders.
- The conference call and webcast provide an opportunity for direct communication between BioNTech's leadership and the investor community, enhancing investor relations.
- BioNTech's commitment to pioneering novel therapies in oncology demonstrates its strategic focus on addressing significant health challenges, potentially positioning the company for future growth.
- The mention of partnerships with global pharmaceutical companies underscores BioNTech's collaborative approach to innovation and resource utilization, which may strengthen its market position.
Potential Negatives
- Notable absence of specific financial expectations or forecasts in the press release could raise concerns among investors about the company's future performance.
- The reliance on partnerships with multiple pharmaceutical companies may indicate a lack of sufficient internal resources or innovation capabilities to independently drive progress.
- The communication about the upcoming financial results does not mention any potentially significant developments or challenges, which could leave stakeholders uninformed about pressing issues facing the company.
FAQ
When will BioNTech announce its Q2 2026 financial results?
BioNTech will announce its second quarter financial results on Tuesday, August 4, 2026.
How can I access the BioNTech conference call?
You can register for the conference call via the provided registration link to receive dial-in details.
What time is the BioNTech conference call scheduled?
The conference call will take place at 8:00 a.m. ET (2:00 p.m. CET) on August 4, 2026.
Will a replay of the conference call be available?
Yes, a replay of the webcast will be available shortly after the call and archived for 30 days.
What is the main focus of BioNTech's research?
BioNTech focuses on developing innovative therapies for cancer and other serious diseases, including mRNA cancer immunotherapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTX Insider Trading Activity
$BNTX insiders have traded $BNTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BNTX stock by insiders over the last 6 months:
- SIERK POETTING (Chief Operating Officer) sold 50,000 shares for an estimated $5,527,960
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BNTX Hedge Fund Activity
We have seen 123 institutional investors add shares of $BNTX stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 1,134,941 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $99,114,397
- JANE STREET GROUP, LLC removed 1,024,464 shares (-75.3%) from their portfolio in Q1 2026, for an estimated $89,466,441
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 670,514 shares (+inf%) to their portfolio in Q1 2026, for an estimated $58,555,987
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 533,664 shares (+213.2%) to their portfolio in Q1 2026, for an estimated $46,604,877
- FLOSSBACH VON STORCH SE removed 515,733 shares (-12.3%) from their portfolio in Q1 2026, for an estimated $45,038,962
- BLACKROCK, INC. added 505,269 shares (+43.8%) to their portfolio in Q1 2026, for an estimated $44,125,141
- FIRST TRUST ADVISORS LP added 451,124 shares (+116.0%) to their portfolio in Q1 2026, for an estimated $39,396,658
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BNTX Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 10 analysts offer price targets for $BNTX in the last 6 months, with a median target of $130.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $119.0 on 07/08/2026
- David Dai from UBS set a target price of $135.0 on 05/27/2026
- Jeffrey Walch from Bernstein set a target price of $96.0 on 05/22/2026
- Mohit Bansal from Wells Fargo set a target price of $140.0 on 05/06/2026
- John Newman from Canaccord Genuity set a target price of $158.0 on 05/06/2026
- Robert Burns from HC Wainwright & Co. set a target price of $130.0 on 04/27/2026
- Etzer Darout from BMO Capital set a target price of $128.0 on 03/11/2026
Full Release
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link . Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link .
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com .
CONTACTS
Investor Relations
Douglas Maffei, PhD
[email protected]
Media Relations
Jasmina Alatovic
[email protected]
